Trial document
DRKS00015231
Trial Description
Title
Prostate bed irradiation with alternative radio-oncological approaches
Trial Acronym
PAROS
URL of the Trial
[---]*
Brief Summary in Lay Language
The PAROS study examines the effects of different radiation techniques on quality of life in the postoperative situation (i.e., after surgery) in three different arms. The standard arm contains a normofractionated irradiation of the prostate, 2 Gy photons are applied on each of the 35 treatment days. The first experimental arm contains a hypofractionated dose irradiation for 19 treatment days with 3 Gy photons each. The 2nd experimental arm hypofractionated irradiation with identical dosage but with protons.
Brief Summary in Scientific Language
As the most common male carcinoma, prostate cancer is a prominent tumor entity in oncology. In addition to definitive radiotherapy, the surgical procedure is considered to be an oncologically equivalent therapeutic alternative for non-metastatic malignancies in the primary setting. However, a subsequent radiotherapy of the prostate bed is often necessary, which takes place as an "adjuvant" treatment immediately after surgery or in the course of a renewed increase in PSA and usually extends over several weeks. For the primary situation (without pre-surgery), several phase III clinical trials have shown that it is possible to shorten radiotherapy by increasing the single dose (called hypofractionation). In the context of two prospective Phase II studies, which were carried out in Heidelberg, it has since been shown that hypofractionation with both photons and protons is safe and feasible even in the postoperative situation.
The current, prospective and randomized PAROS study is now intended to demonstrate a multicentric phase III study as an improvement in the quality of life caused by rectum toxicity (primary endpoint) by the use of protons. The oncological non-inferiority of hypofractionated radiotherapy after surgery is a secondary endpoint.
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00015231
- 2018/09/27
- [---]*
- yes
- Approved
- S-435/2018, Ethik-Kommission I der Medizinischen Fakultät Heidelberg
Secondary IDs
- [---]*
Health Condition or Problem studied
- C61 - Malignant neoplasm of prostate
Interventions/Observational Groups
- photon IMRT normofractionated (35 x 2 Gy)
- photon IMRT hypofractionated (19 x 3 Gy)
- protons hypofractionated (19 x 3 Gy(RBE))
Characteristics
- Interventional
- [---]*
- Randomized controlled trial
- Open (masking not used)
- [---]*
- Active control (effective treament of control group)
- Treatment
- Parallel
- III
- No
Primary Outcome
The primary endpoint: Hypofractionated Proton radiotherapy improves rectal quality of life (using the bowel symptom subscale of the QLQ PR 25) compared to the two photon arms. This is evaluated on the difference 12 weeks after the beginning of radiotherapy vs. baseline.
Secondary Outcome
• Non-inferiority of the hypofractionated therapy arms (arm 2 + 3) compared to the standard arm (arm 1) in terms of biochemical progression-free survival (bPFS) after 5 years. To determine the biochemical lack of recurrence, PSA determinations are carried out consecutively. Two consecutive rises above the nadir are considered recurrences.
• Overall survival (OS) after 5 years
• Quality of life according to EORTC QLQ-C30 after 2 and after 5 years
• clinical symptoms and toxicity
(including mortality) after NCI CTCAE version 5.0 at 2 (and after 5) years
Countries of Recruitment
- Germany
Locations of Recruitment
- University Medical Center
Recruitment
- Actual
- 2018/09/14
- 897
- Monocenter trial
- National
Inclusion Criteria
- Male
- 18 Years
- no maximum age
Additional Inclusion Criteria
- histologically confirmed prostate cancer with classification according to the Gleason score and recent PSA-value
- Indication for the irradiation of the prostate bed (adjuvant / salvage) after prostatectomy
- Karnofsky index ≥ 70%
- Age ≥ 18 years
- Patient information and written consent
- Ability of the patient to consent
Exclusion Criteria
- antihormonal therapy
- lymphoid metastasis
- R2
- Stage IV (distant metastases)
- previous radiotherapy in the pelvis
- hip total endoprosthesis
- Simultaneous participation in another clinical trial that could influence the results of one of the studies
Addresses
-
start of 1:1-Block address primary-sponsor
- Universitätsklinikum HeidelbergAbteilung RadioOnkologie und Strahlentherapie
- Mr. Prof. Dr. Klaus Herfarth
- Im Neuenheimer Feld 400
- 69120 Heidelberg
- Germany
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- 06221 56 8202
- 06221 56 5353
- klaus.herfarth at med.uni-heidelberg.de
- https://www.klinikum.uni-heidelberg.de/Willkommen.116036.0.html
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address scientific-contact
- Universitätsklinikum HeidelbergAbteilung RadioOnkologie und Strahlentherapie
- Mr. Prof. Dr. Klaus Herfarth
- Im Neuenheimer Feld 400
- 69120 Heidelberg
- Germany
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- 06221 56 8202
- 06221 56 5353
- klaus.herfarth at med.uni-heidelberg.de
- https://www.klinikum.uni-heidelberg.de/Willkommen.116036.0.html
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- Universitätsklinikum HeidelbergAbteilung RadioOnkologie und Strahlentherapie
- Studienzentrale Heidelberg
- Im Neuenheimer Feld 400
- 69120 Heidelberg
- Germany
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- 06221 56 36318
- 06221 56 5353
- studien.radonk at med.uni-heidelberg.de
- https://www.klinikum.uni-heidelberg.de/Willkommen.116036.0.html
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- Universitätsklinikum HeidelbergAbteilung RadioOnkologie und Strahlentherapie
- Mr. Prof. Dr. Klaus Herfarth
- Im Neuenheimer Feld 400
- 69120 Heidelberg
- Germany
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- 06221 56 8202
- 06221 56 5353
- klaus.herfarth at med.uni-heidelberg.de
- https://www.klinikum.uni-heidelberg.de/Willkommen.116036.0.html
end of 1:1-Block address contact materialSupport
Status
- Recruiting ongoing
- [---]*
Trial Publications, Results and other Documents
- [---]*